Gomes Viviane H, Barcellos Myla Cb, Lima Virgínia Ct, de Moura Raiane A, de Freitas Jacqueline B, da Silva Marta Fa
Department of Veterinary Medicine and Surgery, Universidade Federal Rural do Rio de Janeiro, UFRRJ, Seropédica, RJ, Brazil.
Department of Veterinary Medicine and Surgery, Universidade Federal Rural do Rio de Janeiro, UFRRJ, Seropédica, RJ, Brazil.
Vet Anaesth Analg. 2019 Jul;46(4):429-434. doi: 10.1016/j.vaa.2019.03.001. Epub 2019 Mar 21.
To evaluate the efficacy of three doses of nalbuphine in reversing sedative and cardiopulmonary effects of morphine-acepromazine in dogs.
Prospective, randomized experimental trial.
A group of eight healthy Beagle dogs, aged 5-6 years and weighing 12.5 ± 2.1 kg.
Dogs were administered morphine (0.5 mg kg) and acepromazine (0.05 mg kg) intravenously (IV). After 20 minutes, dogs were administered one of four treatments IV: saline (control); or nalbuphine (0.3 mg kg; treatment N0.3), (0.6 mg kg; treatment N0.6) or (1.0 mg kg; treatment N1.0), in random order separated by 1 week. Sedation was scored using a numeric descriptive scale (NDS) and simple numerical scale (SNS). Heart rate, systolic arterial pressure (SAP), respiratory rate (f) and rectal temperature (RT) were recorded before (BL), 20 minutes after morphine-acepromazine (T0), then 10 (T10), 30, 60 and 90 minutes after saline or nalbuphine. Arterial blood gases were measured at BL, T0 and T10. Values were compared with BL, T0 and among treatments using anova (p < 0.05) and the Bonferroni correction (p < 0.008).
NDS for N0.6 and SNS for N0.6 and N1.0 at T30, and both scores for all nalbuphine treatments at T60-T90 were lower compared with T0 (p < 0.05). Sedation scores were not different among nalbuphine treatments. SNS scores were lower than control at T10 for N0.3 and N0.6 (p < 0.05). SAP and f were lower than BL for all treatments at some time points (p < 0.05). RT was higher than control at T60 in the nalbuphine treatments (p < 0.001). PaO was lower in N0.3 at T0 compared with BL (p = 0.036).
All nalbuphine doses decreased the degree of sedation, without differences among them. Administration of nalbuphine resulted in minimal changes in measured cardiopulmonary variables.
评估三种剂量的纳布啡逆转吗啡-乙酰丙嗪对犬镇静及心肺效应的疗效。
前瞻性随机试验。
一组8只健康比格犬，年龄5 - 6岁，体重12.5±2.1千克。
犬静脉注射吗啡（0.5毫克/千克）和乙酰丙嗪（0.05毫克/千克）。20分钟后，犬静脉注射以下四种处理之一：生理盐水（对照）；或纳布啡（0.3毫克/千克；处理N0.3）、（0.6毫克/千克；处理N0.6）或（1.0毫克/千克；处理N1.0），随机顺序给药，每次间隔1周。使用数字描述量表（NDS）和简单数字量表（SNS）对镇静程度进行评分。在注射吗啡-乙酰丙嗪前（基础值，BL）、注射后20分钟（T0），以及注射生理盐水或纳布啡后10分钟（T10）、30分钟、60分钟和90分钟记录心率、收缩压（SAP）、呼吸频率（f）和直肠温度（RT）。在基础值、T0和T10测量动脉血气。使用方差分析（p < 0.05）和邦费罗尼校正（p < 0.008）将各值与基础值、T0进行比较，并在各处理组间进行比较。
与T0相比，N0.6组在T30时的NDS评分，以及N0.6和N1.0组在T30时的SNS评分，以及所有纳布啡处理组在T60 - T90时的两项评分均较低（p < 0.05）。纳布啡各处理组间镇静评分无差异。N0.3和N0.6组在T10时的SNS评分低于对照组（p < 0.05）。在某些时间点，所有处理组的SAP和f均低于基础值（p < 0.05）。纳布啡处理组在T60时的RT高于对照组（p < 0.001）。与基础值相比N0.3组在T时的PaO较低（p = 0.036）。
所有纳布啡剂量均降低了镇静程度，各剂量间无差异。纳布啡给药导致所测心肺变量变化极小。
